SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '5EA'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 12	ALA A 99 GLY A 153 LEU A 201 ASP A 212 PHE A 213	ATP A 535 (-3.6A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A) 5EA A1001 (-3.6A)	0.51A	1xkkA-1s9iA: 24.7	1xkkA-1s9iA: 25.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 VAL A 86 ALA A 99 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.53A	2gqgB-1s9iA: 15.0	2gqgB-1s9iA: 23.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	ALA A 99 LYS A 101 VAL A 131 ILE A 145 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.75A	2zvaA-1s9iA: 17.0	2zvaA-1s9iA: 23.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 ALA A 99 VAL A 131 ILE A 145 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.57A	2zvaA-1s9iA: 17.0	2zvaA-1s9iA: 23.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 10	LEU A 78 ALA A 99 LYS A 101 VAL A 131 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.83A	3aoxA-1s9iA: 21.7	3aoxA-1s9iA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	VAL A 86 ALA A 99 GLY A 153 LEU A 201 ASP A 212 PHE A 213	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A) 5EA A1001 (-3.6A)	0.29A	3bbtB-1s9iA: 24.3	3bbtB-1s9iA: 25.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_D_FMMD91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	VAL A 86 ALA A 99 LYS A 101 GLY A 153 LEU A 201 ASP A 212 PHE A 213	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A) 5EA A1001 (-3.6A)	0.41A	3bbtD-1s9iA: 17.1	3bbtD-1s9iA: 25.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 GLY A 79 ALA A 99 VAL A 131 GLY A 153 LEU A 201 CYH A 211	ATP A 535 (-3.9A) ATP A 535 ( 3.9A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) ATP A 535 ( 4.5A)	0.67A	3c7qA-1s9iA: 21.1	3c7qA-1s9iA: 23.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 9	LEU A 78 VAL A 86 VAL A 131 ILE A 145 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 (-4.8A)	0.88A	3cs9B-1s9iA: 22.1	3cs9B-1s9iA: 23.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 9	LEU A 78 VAL A 86 LYS A 101 VAL A 131 ILE A 145	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A)	0.78A	3cs9C-1s9iA: 7.8	3cs9C-1s9iA: 23.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 11	LEU A 78 VAL A 86 ALA A 99 VAL A 131 GLY A 153 LEU A 201 CYH A 211	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) ATP A 535 ( 4.5A)	0.79A	3g0eA-1s9iA: 21.0	3g0eA-1s9iA: 25.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 VAL A 86 ALA A 99 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.55A	3g5dA-1s9iA: 7.5	3g5dA-1s9iA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LXK_A_MI1A1125_1 (TYROSINE-PROTEIN KINASE JAK3)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 GLY A 79 VAL A 86 ALA A 99 LYS A 101 VAL A 131 MET A 147	ATP A 535 (-3.9A) ATP A 535 ( 3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) ATP A 535 ( 3.4A)	0.80A	3lxkA-1s9iA: 9.5	3lxkA-1s9iA: 27.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 11	ALA A 99 VAL A 131 MET A 150 GLY A 153 LEU A 201 ASP A 212	ATP A 535 (-3.6A) 5EA A1001 (-4.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.72A	3miyA-1s9iA: 10.2	3miyA-1s9iA: 26.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 6	VAL A 86 LYS A 101 VAL A 215 VAL A 131 ILE A 145	ATP A 535 (-4.1A) ATP A 535 ( 2.5A) 5EA A1001 (-3.9A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A)	1.19A	3mssD-1s9iA: 21.4	3mssD-1s9iA: 25.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 VAL A 86 ALA A 99 LYS A 101 VAL A 131 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.65A	3octA-1s9iA: 22.3	3octA-1s9iA: 24.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 VAL A 86 ALA A 99 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.48A	3sxrA-1s9iA: 21.9	3sxrA-1s9iA: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	LEU A 78 VAL A 86 ALA A 99 VAL A 131 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.49A	3sxrB-1s9iA: 21.6	3sxrB-1s9iA: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	8 / 12	LEU A 78 ALA A 99 LYS A 101 VAL A 131 ILE A 145 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.62A	3ue4A-1s9iA: 6.9	3ue4A-1s9iA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 VAL A 86 ALA A 99 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.63A	3ue4B-1s9iA: 22.4	3ue4B-1s9iA: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	LEU A 78 VAL A 86 ALA A 99 GLY A 153 CYH A 211 PHE A 213	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 4.7A) ATP A 535 ( 4.5A) 5EA A1001 (-3.6A)	0.67A	3wzdA-1s9iA: 16.8	3wzdA-1s9iA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 11	LEU A 78 ALA A 99 VAL A 131 GLY A 153 LEU A 201 CYH A 211	ATP A 535 (-3.9A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) ATP A 535 ( 4.5A)	0.84A	4agdA-1s9iA: 21.0	4agdA-1s9iA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	11 / 12	LYS A 101 LEU A 119 LEU A 122 ILE A 145 MET A 147 ASP A 194 LYS A 196 ASN A 199 ASP A 212 GLY A 214 VAL A 215	ATP A 535 ( 2.5A) 5EA A1001 (-4.9A) 5EA A1001 (-4.9A) 5EA A1001 ( 3.7A) ATP A 535 ( 3.4A) ATP A 535 ( 3.4A) ATP A 535 (-2.7A) MG A 536 (-2.8A) MG A 536 (-3.3A) 5EA A1001 (-3.6A) 5EA A1001 (-3.9A)	0.47A	4an2A-1s9iA: 39.5	4an2A-1s9iA: 74.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LMN_A_EUIA503_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	12 / 12	LYS A 101 LEU A 119 LEU A 122 ILE A 145 MET A 147 ASN A 199 ASP A 212 PHE A 213 GLY A 214 SER A 216 LEU A 219 MET A 223	ATP A 535 ( 2.5A) 5EA A1001 (-4.9A) 5EA A1001 (-4.9A) 5EA A1001 ( 3.7A) ATP A 535 ( 3.4A) MG A 536 (-2.8A) MG A 536 (-3.3A) 5EA A1001 (-3.6A) 5EA A1001 (-3.6A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.9A) 5EA A1001 (-4.2A)	0.44A	4lmnA-1s9iA: 33.0	4lmnA-1s9iA: 82.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	8 / 12	LEU A 78 VAL A 86 ALA A 99 LYS A 101 VAL A 131 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.68A	4mxxB-1s9iA: 5.7	4mxxB-1s9iA: 26.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	8 / 12	LEU A 78 VAL A 86 ALA A 99 LYS A 101 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.61A	4xeyA-1s9iA: 22.7	4xeyA-1s9iA: 24.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	LEU A 78 VAL A 86 LYS A 101 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.58A	4xeyB-1s9iA: 22.3	4xeyB-1s9iA: 24.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	VAL A 86 ALA A 99 LYS A 101 VAL A 131 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.49A	4xeyB-1s9iA: 22.3	4xeyB-1s9iA: 24.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_2 (PROTEIN-TYROSINE KINASE 6)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	3 / 3	ILE A 145 MET A 150 ASP A 212	5EA A1001 ( 3.7A) None MG A 536 (-3.3A)	0.73A	5h2uA-1s9iA: 17.7	5h2uA-1s9iA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	LEU A 78 VAL A 86 ALA A 99 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.54A	5h2uB-1s9iA: 17.7	5h2uB-1s9iA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	VAL A 86 ALA A 99 ILE A 145 GLY A 153 LEU A 201 ASP A 212	ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.58A	5h2uB-1s9iA: 17.7	5h2uB-1s9iA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 12	ALA A 99 ILE A 145 GLY A 153 LEU A 201 ASP A 212	ATP A 535 (-3.6A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.56A	5h2uC-1s9iA: 17.8	5h2uC-1s9iA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 12	LEU A 78 ALA A 99 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-3.6A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.52A	5h2uC-1s9iA: 17.8	5h2uC-1s9iA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 12	LEU A 78 VAL A 86 ALA A 99 ILE A 145 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.49A	5h2uD-1s9iA: 17.5	5h2uD-1s9iA: 27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 12	VAL A 86 ALA A 99 ILE A 145 CYH A 211 PHE A 213	ATP A 535 (-4.1A) ATP A 535 (-3.6A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.5A) 5EA A1001 (-3.6A)	0.56A	5hesA-1s9iA: 8.3	5hesA-1s9iA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 12	GLY A 81 VAL A 86 ALA A 99 LYS A 101 ILE A 145	ATP A 535 (-3.8A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 ( 3.7A)	0.86A	5hieB-1s9iA: 9.0	5hieB-1s9iA: 24.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	5 / 10	LEU A 78 VAL A 86 ILE A 145 MET A 150 GLY A 153	ATP A 535 (-3.9A) ATP A 535 (-4.1A) 5EA A1001 ( 3.7A) None ATP A 535 ( 4.7A)	0.59A	5mo4A-1s9iA: 5.9	5mo4A-1s9iA: 20.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	VAL A 86 ALA A 99 LYS A 101 ILE A 145 GLY A 153 LEU A 201 PHE A 213	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 ( 3.7A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) 5EA A1001 (-3.6A)	0.83A	5p9iA-1s9iA: 5.7	5p9iA-1s9iA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FNM_A_1N1A1001_1 (-)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	7 / 12	VAL A 86 ALA A 99 LYS A 101 ILE A 145 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 ( 3.7A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.66A	6fnmA-1s9iA: 22.3	6fnmA-1s9iA: 27.30

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"ALA A  99;GLY A 153;LEU A 201;ASP A 212;PHE A 213","ATP A 535 (-3.6A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A);5EA A1001 (-3.6A)","0.51A","1xkkA-1s9iA:24.7",null],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.53A","2gqgB-1s9iA:15.0","1xkkA-1s9iA:25.82"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"ALA A  99;LYS A 101;VAL A 131;ILE A 145;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.75A","2zvaA-1s9iA:17.0","2gqgB-1s9iA:23.63"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;ALA A  99;VAL A 131;ILE A 145;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.57A","2zvaA-1s9iA:17.0","2zvaA-1s9iA:23.82"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;ALA A  99;LYS A 101;VAL A 131;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.83A","3aoxA-1s9iA:21.7","2zvaA-1s9iA:23.82"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"VAL A  86;ALA A  99;GLY A 153;LEU A 201;ASP A 212;PHE A 213","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A);5EA A1001 (-3.6A)","0.29A","3bbtB-1s9iA:24.3","3aoxA-1s9iA:25.06"],["3BBT_D_FMMD91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"VAL A  86;ALA A  99;LYS A 101;GLY A 153;LEU A 201;ASP A 212;PHE A 213","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A);5EA A1001 (-3.6A)","0.41A","3bbtD-1s9iA:17.1","3bbtB-1s9iA:25.91"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;GLY A  79;ALA A  99;VAL A 131;GLY A 153;LEU A 201;CYH A 211","ATP A 535 (-3.9A);ATP A 535 ( 3.9A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);ATP A 535 ( 4.5A)","0.67A","3c7qA-1s9iA:21.1","3bbtD-1s9iA:25.91"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"LEU A  78;VAL A  86;VAL A 131;ILE A 145;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 (-4.8A)","0.88A","3cs9B-1s9iA:22.1","3c7qA-1s9iA:23.62"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"LEU A  78;VAL A  86;LYS A 101;VAL A 131;ILE A 145","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A)","0.78A","3cs9C-1s9iA:7.8","3cs9B-1s9iA:23.69"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;GLY A 153;LEU A 201;CYH A 211","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);ATP A 535 ( 4.5A)","0.79A","3g0eA-1s9iA:21.0","3cs9C-1s9iA:23.69"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.55A","3g5dA-1s9iA:7.5","3g0eA-1s9iA:25.42"],["3LXK_A_MI1A1125_1","TYROSINE-PROTEIN KINASE JAK3","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;GLY A  79;VAL A  86;ALA A  99;LYS A 101;VAL A 131;MET A 147","ATP A 535 (-3.9A);ATP A 535 ( 3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);ATP A 535 ( 3.4A)","0.80A","3lxkA-1s9iA:9.5","3g5dA-1s9iA:26.59"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"ALA A  99;VAL A 131;MET A 150;GLY A 153;LEU A 201;ASP A 212","ATP A 535 (-3.6A);5EA A1001 (-4.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.72A","3miyA-1s9iA:10.2","3lxkA-1s9iA:27.49"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"VAL A  86;LYS A 101;VAL A 215;VAL A 131;ILE A 145","ATP A 535 (-4.1A);ATP A 535 ( 2.5A);5EA A1001 (-3.9A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A)","1.19A","3mssD-1s9iA:21.4","3miyA-1s9iA:26.41"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;VAL A 131;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.65A","3octA-1s9iA:22.3","3mssD-1s9iA:25.42"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.48A","3sxrA-1s9iA:21.9","3octA-1s9iA:24.15"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.49A","3sxrB-1s9iA:21.6","3sxrA-1s9iA:24.79"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",8,"LEU A  78;ALA A  99;LYS A 101;VAL A 131;ILE A 145;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.62A","3ue4A-1s9iA:6.9","3sxrB-1s9iA:24.79"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;ALA A  99;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.63A","3ue4B-1s9iA:22.4","3ue4A-1s9iA:24.72"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"LEU A  78;VAL A  86;ALA A  99;GLY A 153;CYH A 211;PHE A 213","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 4.7A);ATP A 535 ( 4.5A);5EA A1001 (-3.6A)","0.67A","3wzdA-1s9iA:16.8","3ue4B-1s9iA:24.72"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"LEU A  78;ALA A  99;VAL A 131;GLY A 153;LEU A 201;CYH A 211","ATP A 535 (-3.9A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);ATP A 535 ( 4.5A)","0.84A","4agdA-1s9iA:21.0","3wzdA-1s9iA:24.86"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",11,"LYS A 101;LEU A 119;LEU A 122;ILE A 145;MET A 147;ASP A 194;LYS A 196;ASN A 199;ASP A 212;GLY A 214;VAL A 215","ATP A 535 ( 2.5A);5EA A1001 (-4.9A);5EA A1001 (-4.9A);5EA A1001 ( 3.7A);ATP A 535 ( 3.4A);ATP A 535 ( 3.4A);ATP A 535 (-2.7A); MG A 536 (-2.8A); MG A 536 (-3.3A);5EA A1001 (-3.6A);5EA A1001 (-3.9A)","0.47A","4an2A-1s9iA:39.5","4agdA-1s9iA:25.00"],["4LMN_A_EUIA503_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",12,"LYS A 101;LEU A 119;LEU A 122;ILE A 145;MET A 147;ASN A 199;ASP A 212;PHE A 213;GLY A 214;SER A 216;LEU A 219;MET A 223","ATP A 535 ( 2.5A);5EA A1001 (-4.9A);5EA A1001 (-4.9A);5EA A1001 ( 3.7A);ATP A 535 ( 3.4A); MG A 536 (-2.8A); MG A 536 (-3.3A);5EA A1001 (-3.6A);5EA A1001 (-3.6A);5EA A1001 (-4.5A);5EA A1001 ( 3.9A);5EA A1001 (-4.2A)","0.44A","4lmnA-1s9iA:33.0","4an2A-1s9iA:74.29"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",8,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;VAL A 131;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.68A","4mxxB-1s9iA:5.7","4lmnA-1s9iA:82.54"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",8,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.61A","4xeyA-1s9iA:22.7","4mxxB-1s9iA:26.87"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"LEU A  78;VAL A  86;LYS A 101;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.58A","4xeyB-1s9iA:22.3","4xeyA-1s9iA:24.04"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"VAL A  86;ALA A  99;LYS A 101;VAL A 131;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.49A","4xeyB-1s9iA:22.3","4xeyB-1s9iA:24.04"],["5H2U_A_1N1A501_2","PROTEIN-TYROSINE KINASE 6","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",3,"ILE A 145;MET A 150;ASP A 212","5EA A1001 ( 3.7A);None; MG A 536 (-3.3A)","0.73A","5h2uA-1s9iA:17.7","4xeyB-1s9iA:24.04"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"LEU A  78;VAL A  86;ALA A  99;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.54A","5h2uB-1s9iA:17.7","5h2uA-1s9iA:27.76"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"VAL A  86;ALA A  99;ILE A 145;GLY A 153;LEU A 201;ASP A 212","ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.58A","5h2uB-1s9iA:17.7","5h2uB-1s9iA:27.76"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"ALA A  99;ILE A 145;GLY A 153;LEU A 201;ASP A 212","ATP A 535 (-3.6A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.56A","5h2uC-1s9iA:17.8","5h2uB-1s9iA:27.76"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"LEU A  78;ALA A  99;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-3.6A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.52A","5h2uC-1s9iA:17.8","5h2uC-1s9iA:27.76"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",6,"LEU A  78;VAL A  86;ALA A  99;ILE A 145;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.49A","5h2uD-1s9iA:17.5","5h2uC-1s9iA:27.76"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"VAL A  86;ALA A  99;ILE A 145;CYH A 211;PHE A 213","ATP A 535 (-4.1A);ATP A 535 (-3.6A);5EA A1001 ( 3.7A);ATP A 535 ( 4.5A);5EA A1001 (-3.6A)","0.56A","5hesA-1s9iA:8.3","5h2uD-1s9iA:27.76"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"GLY A  81;VAL A  86;ALA A  99;LYS A 101;ILE A 145","ATP A 535 (-3.8A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 ( 3.7A)","0.86A","5hieB-1s9iA:9.0","5hesA-1s9iA:25.07"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",5,"LEU A  78;VAL A  86;ILE A 145;MET A 150;GLY A 153","ATP A 535 (-3.9A);ATP A 535 (-4.1A);5EA A1001 ( 3.7A);None;ATP A 535 ( 4.7A)","0.59A","5mo4A-1s9iA:5.9","5hieB-1s9iA:24.87"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"VAL A  86;ALA A  99;LYS A 101;ILE A 145;GLY A 153;LEU A 201;PHE A 213","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 ( 3.7A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);5EA A1001 (-3.6A)","0.83A","5p9iA-1s9iA:5.7","5mo4A-1s9iA:20.79"],["6FNM_A_1N1A1001_1","-","1s9i","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","Homo sapiens",7,"VAL A  86;ALA A  99;LYS A 101;ILE A 145;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 ( 3.7A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.66A","6fnmA-1s9iA:22.3","5p9iA-1s9iA:24.31"]]